Warning! GuruFocus detected
2 Severe warning signs
with 0FY.
Try a 7-Day Free Trial
to check it out.
What is a stock summary page? Click here for an overview.
Business Description
Equillium Inc
NAICS : 325412
SIC : 2834
ISIN : US29446K1060
Description
Equillium Inc is a biotechnology developing therapies to treat severe autoimmune and inflammatory disorders. Its pipeline includes itolizumab, a first-in-class antibody targeting the CD6-ALCAM pathway which plays a key role in the modulation of effector T cells - currently in a Ph 3 study for patients with acute graft-versus-host disease and a Ph 1b study for patients with lupus nephritis. EQ101, a first-in-class cytokine inhibitor that selectively targets IL-2, IL-9, and IL-15 is Ph2-ready and expected to begin enrolling patients in an alopecia areata study in 2H 2022. EQ102, a cytokine inhibitor that selectively targets IL-15 and IL-21, is ready for clinical development and expected to begin enrolling patients in a Ph 1study including patients with celiac disease.
Financial Strength
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 58.79 | |||||
| Equity-to-Asset | 0.74 | |||||
| Debt-to-Equity | 0.02 | |||||
| Debt-to-EBITDA | -0.05 | |||||
| Interest Coverage | N/A |
N/A
|
N/A
| |||
| Piotroski F-Score | 4/9 | |||||
| Altman Z-Score | -7.54 | |||||
| Beneish M-Score | -1.22 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | 45.4 | |||||
| 3-Year EPS without NRI Growth Rate | 44.7 | |||||
| 3-Year FCF Growth Rate | 21.4 | |||||
| 3-Year Book Growth Rate | -38.1 | |||||
| Future 3-5Y EPS without NRI Growth Rate Estimate | -48.22 |
Momentum Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 34.22 | |||||
| 9-Day RSI | 31.07 | |||||
| 14-Day RSI | 32.72 | |||||
| 3-1 Month Momentum % | -0.89 | |||||
| 6-1 Month Momentum % | -8.71 | |||||
| 12-1 Month Momentum % | -68.79 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 3.93 | |||||
| Quick Ratio | 3.93 | |||||
| Cash Ratio | 3.55 | |||||
| Days Sales Outstanding | 40.96 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -6.5 | |||||
| Shareholder Yield % | 13.47 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Operating Margin % | -20.12 | |||||
| Net Margin % | -19.63 | |||||
| FCF Margin % | -46.35 | |||||
| ROE % | -37.23 | |||||
| ROA % | -20.47 | |||||
| ROIC % | -94.12 | |||||
| 3-Year ROIIC % | -965.85 | |||||
| ROC (Joel Greenblatt) % | -860.24 | |||||
| ROCE % | -35.13 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Forward PE Ratio | 1.21 | |||||
| PS Ratio | 0.39 | |||||
| PB Ratio | 0.83 | |||||
| Price-to-Tangible-Book | 0.82 | |||||
| EV-to-EBIT | 0.65 | |||||
| EV-to-EBITDA | 0.66 | |||||
| EV-to-Revenue | -0.12 | |||||
| EV-to-Forward-Revenue | 0.08 | |||||
| EV-to-FCF | 0.26 | |||||
| Price-to-Net-Current-Asset-Value | 0.86 | |||||
| Price-to-Net-Cash | 0.99 | |||||
| Earnings Yield (Greenblatt) % | 153.85 | |||||
| FCF Yield % | -111.37 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Equillium Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 37.854 | ||
| EPS (TTM) (€) | -0.218 | ||
| Beta | 0.33 | ||
| 3-Year Sharpe Ratio | 0.04 | ||
| 3-Year Sortino Ratio | 0.09 | ||
| Volatility % | 119.79 | ||
| 14-Day RSI | 32.72 | ||
| 14-Day ATR (€) | 0.068857 | ||
| 20-Day SMA (€) | 0.58915 | ||
| 12-1 Month Momentum % | -68.79 | ||
| 52-Week Range (€) | 0.3425 - 2.075 | ||
| Shares Outstanding (Mil) | 35.61 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Equillium Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Equillium Inc Stock Events
| Event | Date | Price (€) | ||
|---|---|---|---|---|
| No Event Data | ||||
Equillium Inc Frequently Asked Questions
What is Equillium Inc(FRA:0FY)'s stock price today?
The current price of FRA:0FY is €0.38. The 52 week high of FRA:0FY is €2.08 and 52 week low is €0.34.
When is next earnings date of Equillium Inc(FRA:0FY)?
The next earnings date of Equillium Inc(FRA:0FY) is 2025-05-09 Est..
Does Equillium Inc(FRA:0FY) pay dividends? If so, how much?
Equillium Inc(FRA:0FY) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers